This study is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of LGT209 in hypercholesterolemic patients taking common statin medications and in healthy volunteers.
Age range
18 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of subjects (patients and healthy volunteers) with adverse events, serious adverse events and death
Timeframe: 12 weeks
Plasma concentrations of LGT209 following subcutaneous administration
Timeframe: 12 weeks
Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) concentration
Timeframe: baseline and 12 weeks
Change from baseline in low density lipoprotein-cholesterol (LDL-C) concentration
Timeframe: baseline and 12 weeks